ACADIA Pharmaceuticals (MEX:ACAD) Total Stockholders Equity: MXN22,506 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN453.75
GF Value MXN437.56
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Total Stockholders Equity?

ACADIA Pharmaceuticals MEX:ACAD 73 Total Stockholders Equity is MXN22,506 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN437.56 (Fairly Valued). The stock has 10 warning signs investors should review.

ACADIA Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was MXN22,506 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ACADIA Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was MXN131.55. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ACADIA Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.04.

ACADIA Pharmaceuticals  (MEX:ACAD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ACADIA Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(22506-0)/171.086
=131.55

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ACADIA Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(212.624 + 703.329) / 22506
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Total Stockholders Equity Related Terms

ACADIA Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Total Stockholders Equity Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,095.90 7,806.45 7,328.72 15,282.91 22,100.02

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,655.37 15,484.80 16,826.62 22,100.02 22,506.00
MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN22,506 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Total Stockholders Equity of MXN22,506 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Total Stockholders Equity too high?
ACADIA Pharmaceuticals' current Total Stockholders Equity is MXN22,506 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Total Stockholders Equity compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Total Stockholders Equity of MXN22,506 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Total Stockholders Equity is MXN22,506 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN437.56, compared to a current price of MXN453.75 — trading 3.7% above its estimated fair value. The current Total Stockholders Equity is MXN22,506 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Total Stockholders Equity is MXN22,506 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN453.75 is trading 3.7% above its estimated GF Value™ of MXN437.56. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Total Stockholders Equity: MXN22,506 Mil
  • GF Value™: MXN437.56 vs. price of MXN453.75 (3.7% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN453.75
Price
MXN437.56
GF Value